Probability of achieving requisite pharmacodynamic exposure for oral β-lactam regimens against Haemophilus influenzae in children

Pediatric Drugs

Volumn 10, Issue 6, 2008, Pages 391-397

  Pichichero, Michael E ^a   Doern, Gary V ^b   Kuti, Joseph L ^c   Nicolau, David P ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HEALTH CARE   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Amoxicillin, pharmacodynamics; Amoxicillin clavulanic acid, pharmacodynamics; Cefaclor, pharmacodynamics; Cefdinir, pharmacodynamics; Cefixime, pharmacodynamics; Cefpodoxime, pharmacodynamics; Cefprozil, pharmacodynamics; Ceftibuten, pharmacodynamics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; BETA LACTAMASE; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; ENZYME SYNTHESIS; HAEMOPHILUS INFLUENZAE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINUSITIS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CHILD; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; OTITIS MEDIA; RESPIRATORY TRACT INFECTIONS;

EID: 55949118209     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/0148581-200810060-00006     Document Type: Article

References (26)

1. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004; 23 (9): 824-8
2. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23 (9): 829-33
3. Kahn W, Ross S, Rodriguez W, et al. Haemophilus influenzae type b resistant to ampicillin: a report of two cases. JAMA 1974; 229: 298-301
4. Tomeh MO, Starr SE, McGowan Jr JE, et al. Ampicillin-resistant Haemophilus influenzae type b infection. JAMA 1974; 229: 295-7
5. Doern GV, Jones RN, Pfaller MA, et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1999; 43 (2): 385-9
6. Credito KL, Lin G, Pankuch GA, et al. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 2001; 45 (1): 67-72
7. Heilmann KP, Rice C, Miller N, et al. The decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 2005; 49: 2561-4
8. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003; 22 (11): 982-92
9. AAP Subcommittee on Management of Sinusitis, AAP Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics 2001; 108 (3): 798-808
10. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngology-Head Neck Surg 2004; 130 Suppl. 1: 1-45
11. AAP and AAFP Subcommittee on Management of Acute Otitis Media. Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics 2004; 113 (5): 1451-65
12. Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40
13. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States: as fluoroquinolones resistance emerges, have we turned the corner on resistance to other antimicrobial classes? Clin Infect Dis 2005; 41: 139-48
14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. 7th ed. CLSI document M7-A7. Wayne (PA): Clinical and Laboratory Standards Institute, 2006
15. Swenson JM, Hindler JA, Jorgensen JH. Special phenotypic methods for detecting antibacterial resistance. In: Murray PR, Baron EJ, Jorgensen JH, et al., editors. Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press, 2003: 1178-95
16. Kilian M. A rapid method for the differentiation of Haemophilus strains: the porphyrin test. Acta Pathol Microbiol Scand 1974; 82: 835-42
17. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996; 15: 949-54
18. Kearns GL, Abdel-Rahman SM, Jacobs RF, et al. Cefpodoxime pharmacokinetics in children: effect of food. Pediatr Infect Dis J 1998; 17: 799-804
19. Nicolau DP, Sutherland CS, Arguedos A, et al. Pharmacokinetics of cefprozil in plasma and middle ear fluid in children undergoing treatment for acute otitis media. Pediatr Drugs 2007; 9 (2): 119-23
20. Kearns GL, Reed MD, Jacobs RF, et al. Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children. Antimicrob Agents Chemother 1991; 35: 2078-84
21. Ginsburg CM, McCracken GH, Petruska M, et al. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985; 28 (4): 504-7
22. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Clin Ther 2005; 27 (11): 1820-30
23. Center for Disease Control and Prevention. Weight-for-age percentiles: boys, 2 to 20 years [online]. Available from URL: http://www.cdc.gov/nchs/data/ ad/ad314.pdf [Accessed 2007 Jan 31]
24. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Inf Dis 1998; 27: 10-22
25. Chatterjee A, Moland ES, Song W, et al. In vitro activity of cefdinir and comparison agents against β-lactamase-producing pathogens. Infect Dis Clin Pract 2005; 13 (3): 108-14
26. Pichichero ME, Reed MD. Variations of pharmacokinetic/pharmacodynamic (PK/PD) of amoxicillin may explain treatment failures in acute otitis media. Pediatric Drugs. In press